Table 5.
Class | Entity | No mentions | No unique mentions | No labels included |
---|---|---|---|---|
Nanomedicine description | Company | 197 | 69 | 41 |
FDA approval date | 34 | 19 | 41 | |
Trade name | 6,716 | 41 | 41 | |
US patent | 31 | 31 | 8 | |
Physicochemical characterization | Active ingredient | 2,161 | 61 | 41 |
Core composition | 89 | 26 | 16 | |
Molecular weight | 50 | 40 | 34 | |
Nanoparticle | 854 | 42 | 41 | |
Particle diameter | 7 | 6 | 6 | |
Surface coating | 62 | 11 | 15 | |
Pharmacokinetic parameters | AUC | 47 | 46 | 19 |
Clearance | 49 | 46 | 24 | |
Cmax | 45 | 42 | 20 | |
Elimination half-life | 16 | 15 | 11 | |
Plasma half-life | 56 | 53 | 13 | |
Tmax | 30 | 18 | 14 | |
Volume of distribution | 29 | 27 | 19 | |
Exposure | Dose | 2,283 | 542 | 41 |
Route of administration | 1,192 | 20 | 41 | |
Biologic response | Adverse reaction | 6,689 | 1,773 | 41 |
Indication | 1,396 | 162 | 41 |
Abbreviations: AUC, area under the curve; Cmax, maximum concentration measured in blood; FDA, US food and drug administration; Tmax, time to reach Cmax.